Introduction
Gastric cancer is a leading cause of death by cancer worldwide and is the fifth most common cancer. 1 Gastric cancer in particular ranks as the third major malignancy in terms of mortality. Approximately 951,000 new cases of gastric cancer and 723,000 deaths were estimated worldwide in 2012. 1 Gastric cancer is classified as cardia and noncardia types in anatomy, and the latter makes up the major part of the cases. Gastric cancer is a multifactorial and complex disease that involves numerous environmental and lifestyle factors, including smoking and poor diet, and Helicobacter pylori infection may increase the development of gastric cancer. 2 Causes of gastric cancer are still unclear and genetic effects, especially single-nucleotide polymorphism (SNP), attract more attention to the study of gene polymorphism in relation to gastric cancer. 3, 4 Interleukin-4 (IL-4) is identified as a contributing factor to gastric carcinogenesis, and it is an indispensable element in the inflammation pathway and is considered as a basic part of the oncogenic process in gastric cancer. 5, 6 IL-4 plays a vital role in tumor immunology, differentiation of hematopoietic cell, and maturation of T-helper (Th) cells to the Th2 phenotype. 7 IL-4 gene is located on chromosome 5q31-33. The IL-4 gene rs2243250 polymorphism, C to T base substitution at -590 of the IL-4 promoter, 
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Zhang et al increases the IL-4 expression. 5 Therefore, the polymorphism may modify the intensity of the inflammatory response, which contributes to gastric cancer development. 8 Numerous studies addressed the association between IL-4 rs2243250 polymorphism and risk of developing gastric cancer. In the past 2 years, two meta-analyses investigated the association. 9, 10 Interestingly, the conclusions of the two previous meta-analyses were contradictory. In addition, more case-control studies have been published during these past 2 years. Based on all these factors, we performed this meta-analysis to try and find a more precise result on the association between IL-4 rs2243250 polymorphism and risk of developing gastric cancer. 
Materials and methods

study selection criteria
Studies were included in this meta-analysis if they met the following criteria: 1) had a case-control design; 2) examined the association between IL-4 rs2243250 polymorphism and gastric cancer susceptibility; 3) included patients who were diagnosed with gastric cancer and controls who were cancer free; and 4) had sufficient data for calculating odds ratios (ORs) and corresponding 95% confidence intervals (CIs). In addition, we excluded the following: 1) unpublished studies or abstracts; 2) studies in which the genotype distributions were not reported; and 3) studies in nonhuman subjects.
Data extraction
Two authors extracted the following information from the included studies: author name, publication year, country, ethnicity of the study subject, sample size, genotype distribution, and Hardy-Weinberg equilibrium (HWE) for controls. In addition, any disagreements were resolved by discussion.
statistical analysis
The χ 2 test was used to examine whether the genotype frequencies in controls were consistent with HWE. The ORs and corresponding 95% CIs were calculated to assess the strength of association between IL-4 rs2243250 polymorphism and gastric cancer susceptibility using the following five genetic models: allelic contrast (T vs C), homozygote contrast (TT vs CC), heterozygote contrast (CT vs CC), dominant model (TT + CT vs CC), and recessive model (TT vs CT + CC). 5, [11] [12] [13] Heterogeneity was detected using the Q-test and I 2 statistic.
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The random-effects model was employed to aggregate the results of the included studies, which reduces to fixed-effects model when no between-study heterogeneity exists. Sensitivity analysis by excluding studies not in HWE in controls and subgroup analyses based on ethnicity were also performed. Publication bias was assessed by funnel plot and Egger's linear regression test to quantitatively measure the asymmetry of funnel plots. 15 The α level of significance was set at 0.05, except for the Q-test for heterogeneity (0.1).
Results
study characteristics
Of the 95 records retrieved initially, a total of eleven published case-control studies 7, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] were ultimately identified involving 2,247 gastric cancer patients and 3,370 controls. Figure 1 shows the detailed flowchart of the study selection process. Table 1 lists the main characteristics of the included studies. Four studies 7, 16, 19, 21 involved Caucasian populations, and seven studies 17, 18, 20, [22] [23] [24] [25] involved Asians. The genotype distributions of controls from five studies 16, 17, 20, 23, 24 were inconsistent with HWE.
Meta-analysis
The main results of this meta-analysis are listed in Table 2 . Overall, no significant relationship was observed between IL-4 rs2243250 polymorphism and gastric cancer susceptibility in the total populations (T vs C: OR =1.05, 95% CI =0.95-1.17; TT vs CC: OR =1.20, 95% CI =0.89-1.63, Figure 2 ; CT vs CC: 1.14, 95% CI =0.87-1.48; TT + CT vs CC: OR =1.13, 95% CI =0.89-1.44; TT vs CT + CC: OR =1.02, 95% CI =0.88-1.20). Similarly, in the succeeding sensitivity analysis by excluding studies not in HWE in controls, no significant association was found between IL-4 rs2243250 polymorphism and gastric cancer susceptibility in the total populations (Table 2) . Finally, even in the stratified analysis by ethnicity, we did not observe any significant association between IL-4 rs2243250 polymorphism and gastric cancer susceptibility (Table 2) .
Publication bias
Begg's funnel plot seemed symmetric for all five genetic models. Figure 3 shows the shapes of the funnel plots of Table 2 ).
Discussion
Nowadays, genetic susceptibility in cancer development, especially SNPs, has drawn a great attention to the research of gene variation involved in carcinogenesis. 26, 27 Gastric cancer is a multifactorial and complicated disease in which gene effects have been considered as a predominant component. 
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IL-4 polymorphism and gastric cancer risk
With the development of molecular epidemiology, numerous studies addressed the effects of IL-4 rs2243250 polymorphism on gastric cancer susceptibility. In 2003, El-Omar et al 16 investigated the proinflammatory cytokine gene polymorphism on the risk of noncardia gastric cancer and indicated that IL-4 was not associated with any of the cancers studied. However, subsequent studies did not reveal similar results, 10,21 and the conclusion of the relationship between IL-4 rs2243250 polymorphism and gastric cancer susceptibility remains controversial. This meta-analysis included eleven published case-control studies and was conducted to evaluate the true association between IL-4 rs2243250 polymorphism and gastric cancer susceptibility; no significant difference was observed in overall analysis. Sensitivity analysis by excluding studies not in HWE in controls and subgroup analysis according to ethnicity also showed similar results.
In 2013, Zhang et al 9 performed a meta-analysis in which they investigated the IL-4 rs2243250 polymorphism and risk of cancer and suggested that the IL-4 rs2243250 polymorphism was not associated with increased/decreased risk of cancer. In their work, they identified eight casecontrol studies evaluating the association between the IL-4 rs2243250 polymorphism and risk of gastric cancer, two of which were unpublished master thesis in the People's Republic of China. 9 As we all know, the unpublished studies were not evaluated by peer review, and more biases would be incurred if they were included in the meta-analysis. In 2014, Sun et al 10 carried out a meta-analysis to investigate the association between IL-4 rs2243250 polymorphism and risk of gastric cancer with only seven case-control studies and suggested that IL-4 rs2243250 polymorphism was associated with a lower gastric cancer risk under dominant model and allelic model in Caucasian. With respect to the aforementioned controversial results, we performed this meta-analysis with the most compressively literature search and excluded the unpublished studies.
Limitations
Like any meta-analysis study, this meta-analysis also has some limitations that should be taken into consideration. [28] [29] [30] [31] First, these results are based on unadjusted estimates, which would be biased by other factors, such as other genes and environment. 32 Second, the sample size of this study is relatively small. Therefore, the statistical power to investigate the true association between IL-4 rs2243250 polymorphism and gastric cancer susceptibility is relatively low, and the evidence in this meta-analysis might be less powerful. Third, even though we did not detect any evidence of between-study heterogeneity in the total population, we observed moderateto-substantial between-study heterogeneity for Caucasians in allele contrast and heterozygote contrast models. This heterogeneity might be derived from the genotyping method, type of disease, and/or diverse environmental circumstances.
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Furthermore, we did not perform stratification analysis according to disease type (cardia and noncardia) due to insufficient original data. In spite of these limitations, this study currently is the best available evidence with a more comprehensive literature search and no publication bias, as compared with the previous meta-analyses.
Conclusion
Despite these limitations, our meta-analysis indicated that IL-4 rs2243250 polymorphism may not be associated with gastric cancer susceptibility. Further large-scale and welldesigned studies are necessary to validate this conclusion.
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